This information comes to us from the Global Action on Aging, based in New York City. The copyright at the bottom of the page is for 2002, so my best guess is that this is an old article. However, I wanted to post it here because it gives some insight into the care policy in Denmark.
This post comes to us curtsy of Stanford University’s Geriatrics department. It is about how the prevalence of Alzheimer’s disease is low in India and some reasons why this may be. One of the possible reasons discussed is relating to diet, and particularly to their use of Curcumin – one of the main ingredients in the spice Turmeric, which is used in many curry dishes (a spice known for anti-inflammatory effects). If you want to read more on this, check out my post on Curry helping the brain repair itself (også på dansk her).
According to recent studies conducted in Indians, the prevalence of dementia is lower compared to that of developed nations. These studies show that prevalence of dementia varies in different region of the country:
• in urban regions it varied from 18 per 1000(1.8%) (Vas et al, 2001) to 33.6 per 1000 (3.36%) (Shaji, 2005)
• in rural areas it was found to be 1.36% to 3.5%. The predominant type of dementia prevalent is dementia of Alzheimer’s type, and the next being vascular dementia.
The prevalence of Alzheimer’s disease is very low in India, but the predilection to diabetes and coronary artery disease increases the risk of multi-infarct dementia.
This is a re-post from GeriPal – Geriatrics and Palliative Care Blog, you can also read the article at GeriPal and check out some of their other posts.
Embracing Direct-to-Consumer Advertising by Focusing on Stopping Medications
There are plenty of examples of direct-to-consumer advertising that the pharmaceutical industry use to lure new customers. Just like the Cancer Center ads we discussed in the last GeriPal post, these ads almost universally do this by making emotional appeals to the consumer, as well as focusing on the benefits rather than presenting any real discussion of risks.
What if someone used a similar concept, but instead of trying to get people to take a drug, they try to convince patients to stop one. That’s just what Cara Tannenbaum and colleagues did in a paper published in JAMA IM, albeit they called it direct-to-consumer patient education and empowerment.